Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Wu, Jiaxin, Wang, Aoli, Li, Xixiang, Chen, Cheng, Qi, Ziping, Hu, Chen, Wang, Wenliang, Wu, Hong, Huang, Tao, Zhao, Ming, Wang, Wenchao, Hu, Zhenquan, Liu, Qingwang, Wang, Beilei, Wang, Li, Li, Lili, Ge, Jian, Ren, Tao, Xia, Ruixiang, Liu, Jing, Liu, Qingsong
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606039/
https://ncbi.nlm.nih.gov/pubmed/30894066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579958
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars